Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003 Jan 01; 101(1):6-14.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Drug Administration Schedule
Female
Humans
Leukemia, B-Cell
Male
Middle Aged
Risk Factors
Rituximab
Severity of Illness Index
Survival Analysis
Treatment Outcome
Vidarabine

authors with profiles

Richard A. Larson
James W. Vardiman